168 related articles for article (PubMed ID: 35004324)
1. Case Report: Sirolimus Alleviates Persistent Cytopenia After CD19 CAR-T-Cell Therapy.
Xing L; Wang Y; Liu H; Gao S; Shao Q; Yue L; Liu Z; Wang H; Shao Z; Fu R
Front Oncol; 2021; 11():798352. PubMed ID: 35004324
[TBL] [Abstract][Full Text] [Related]
2. Persistent Cytopenia After CD19 CAR T Therapy in Relapsed/Refractory DLBCL Patients Could Be a Predictor of Efficacy and Side Effects.
Li J; Mu J; Wang J; Li X; Li Q; Jiang Y; Cui R; Deng Q
Cell Transplant; 2024; 33():9636897241247951. PubMed ID: 38651796
[TBL] [Abstract][Full Text] [Related]
3. Phase I Trial of Fourth-Generation Anti-CD19 Chimeric Antigen Receptor T Cells Against Relapsed or Refractory B Cell Non-Hodgkin Lymphomas.
Zhou X; Tu S; Wang C; Huang R; Deng L; Song C; Yue C; He Y; Yang J; Liang Z; Wu A; Li M; Zhou W; Du J; Guo Z; Li Y; Jiao C; Liu Y; Chang LJ; Li Y
Front Immunol; 2020; 11():564099. PubMed ID: 33329526
[TBL] [Abstract][Full Text] [Related]
4. Phase II trial of co-administration of CD19- and CD20-targeted chimeric antigen receptor T cells for relapsed and refractory diffuse large B cell lymphoma.
Sang W; Shi M; Yang J; Cao J; Xu L; Yan D; Yao M; Liu H; Li W; Zhang B; Sun K; Song X; Sun C; Jiao J; Qin Y; Sang T; Ma Y; Wu M; Gao X; Cheng H; Yan Z; Li D; Sun H; Zhu F; Wang Y; Zeng L; Li Z; Zheng J; Xu K
Cancer Med; 2020 Aug; 9(16):5827-5838. PubMed ID: 32608579
[TBL] [Abstract][Full Text] [Related]
5. Dual specific CD19/CD22-targeted chimeric antigen receptor T-cell therapy for refractory diffuse large B-cell lymphoma: A case report.
Huang C; Zhang HC; Ho JY; Liu RX; Wang L; Kuang N; Zheng MR; Liu LH; Li JQ
Oncol Lett; 2020 Oct; 20(4):21. PubMed ID: 32774494
[TBL] [Abstract][Full Text] [Related]
6. Prolonged cytopenias after immune effector cell therapy and lymphodepletion in patients with leukemia, lymphoma and solid tumors.
Miller A; Daum R; Wang T; Wu M; Tat C; Pfeiffer T; Navai S; Heczey A; Hegde M; Ahmed N; Whittle SB; Hill L; Martinez C; Krance R; Ramos CA; Rouce RH; Lulla P; Heslop HE; Omer B; Shekar M
Cytotherapy; 2024 May; ():. PubMed ID: 38819365
[TBL] [Abstract][Full Text] [Related]
7. Thrombopoietin receptor agonists for acquired thrombocytopenia following anti-CD19 CAR-T-cell therapy: a case report.
Baur R; Jitschin R; Kharboutli S; Stoll A; Völkl S; Büttner-Herold M; Schmidt D; Rösler W; Mackensen A; Mougiakakos D
J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34272307
[TBL] [Abstract][Full Text] [Related]
8. [Efficacy and safety of CD19 chimeric antigen receptor T cells for the treatment of 22 patients with B-cell lymphoma].
Xiao X; Jiang YY; Cao YQ; Li Q; Jin X; Meng JX; Sui T; Li YM; Zhao MF
Zhonghua Xue Ye Xue Za Zhi; 2019 Apr; 40(4):276-280. PubMed ID: 31104437
[No Abstract] [Full Text] [Related]
9. Cytopenias After CD19 Chimeric Antigen Receptor T-Cells (CAR-T) Therapy for Diffuse Large B-Cell Lymphomas or Transformed Follicular Lymphoma: A Single Institution Experience.
Schaefer A; Huang Y; Kittai A; Maakaron JE; Saygin C; Brammer J; Penza S; Saad A; Jaglowski SM; William BM
Cancer Manag Res; 2021; 13():8901-8906. PubMed ID: 34876852
[TBL] [Abstract][Full Text] [Related]
10. The European Medicines Agency Review of Kymriah (Tisagenlecleucel) for the Treatment of Acute Lymphoblastic Leukemia and Diffuse Large B-Cell Lymphoma.
Ali S; Kjeken R; Niederlaender C; Markey G; Saunders TS; Opsata M; Moltu K; Bremnes B; Grønevik E; Muusse M; Håkonsen GD; Skibeli V; Kalland ME; Wang I; Buajordet I; Urbaniak A; Johnston J; Rantell K; Kerwash E; Schuessler-Lenz M; Salmonson T; Bergh J; Gisselbrecht C; Tzogani K; Papadouli I; Pignatti F
Oncologist; 2020 Feb; 25(2):e321-e327. PubMed ID: 32043764
[TBL] [Abstract][Full Text] [Related]
11. Anti-CD19 chimeric antigen receptor T-cell therapy in acute lymphocytic leukaemia: a systematic review and meta-analysis.
Anagnostou T; Riaz IB; Hashmi SK; Murad MH; Kenderian SS
Lancet Haematol; 2020 Nov; 7(11):e816-e826. PubMed ID: 33091355
[TBL] [Abstract][Full Text] [Related]
12. Thrombopoietin receptor agonist for treating bone marrow aplasia following anti-CD19 CAR-T cells-single-center experience.
Beyar-Katz O; Perry C; On YB; Amit O; Gutwein O; Wolach O; Kedar R; Pikovsky O; Avivi I; Gold R; Ben-Ezra J; Shasha D; Ami RB; Ram R
Ann Hematol; 2022 Aug; 101(8):1769-1776. PubMed ID: 35731278
[TBL] [Abstract][Full Text] [Related]
13. A Case of Relapsed Primary Central Nervous System Lymphoma Treated with CD19-directed Chimeric Antigen Receptor T Cell Therapy.
Mizuta R; Otani Y; Fujii K; Uneda A; Ishida J; Tanaka T; Ikegawa S; Fujii N; Maeda Y; Date I
NMC Case Rep J; 2022; 9():275-280. PubMed ID: 36238605
[TBL] [Abstract][Full Text] [Related]
14. Clinical Efficacy and Tumor Microenvironment Influence in a Dose-Escalation Study of Anti-CD19 Chimeric Antigen Receptor T Cells in Refractory B-Cell Non-Hodgkin's Lymphoma.
Yan ZX; Li L; Wang W; OuYang BS; Cheng S; Wang L; Wu W; Xu PP; Muftuoglu M; Hao M; Yang S; Zhang MC; Zheng Z; Li J; Zhao WL
Clin Cancer Res; 2019 Dec; 25(23):6995-7003. PubMed ID: 31444250
[TBL] [Abstract][Full Text] [Related]
15. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study.
Abramson JS; Palomba ML; Gordon LI; Lunning MA; Wang M; Arnason J; Mehta A; Purev E; Maloney DG; Andreadis C; Sehgal A; Solomon SR; Ghosh N; Albertson TM; Garcia J; Kostic A; Mallaney M; Ogasawara K; Newhall K; Kim Y; Li D; Siddiqi T
Lancet; 2020 Sep; 396(10254):839-852. PubMed ID: 32888407
[TBL] [Abstract][Full Text] [Related]
16. Long-Term Follow-Up of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy.
Cappell KM; Sherry RM; Yang JC; Goff SL; Vanasse DA; McIntyre L; Rosenberg SA; Kochenderfer JN
J Clin Oncol; 2020 Nov; 38(32):3805-3815. PubMed ID: 33021872
[TBL] [Abstract][Full Text] [Related]
17. Systematic Review and Meta-analysis of CD19-Specific CAR-T Cell Therapy in Relapsed/Refractory Acute Lymphoblastic Leukemia in the Pediatric and Young Adult Population: Safety and Efficacy Outcomes.
Aamir S; Anwar MY; Khalid F; Khan SI; Ali MA; Khattak ZE
Clin Lymphoma Myeloma Leuk; 2021 Apr; 21(4):e334-e347. PubMed ID: 33573914
[TBL] [Abstract][Full Text] [Related]
18. CAR-T Cell Therapy for Acute Lymphoblastic Leukemia: Transforming the Treatment of Relapsed and Refractory Disease.
Pehlivan KC; Duncan BB; Lee DW
Curr Hematol Malig Rep; 2018 Oct; 13(5):396-406. PubMed ID: 30120708
[TBL] [Abstract][Full Text] [Related]
19. Safety and Efficacy of Anti-CD19-Chimeric Antigen Receptor T Cell Combined With Programmed Cell Death 1 Inhibitor Therapy in a Patient With Refractory Post-Transplant Lymphoproliferative Disease: Case Report and Literature Review.
Feng G; Li Q; Zhu H; Jiang Y; Yuan J; Fu Y; Deng Q
Front Oncol; 2021; 11():726134. PubMed ID: 34604065
[TBL] [Abstract][Full Text] [Related]
20. A case of successful CAR-T cell therapy for early isolated CNS recurrence of DLBCL with persistent CAR-T cells.
Takigawa K; Kawano N; Mori Y; Yamauchi T; Tochigi T; Miyawaki K; Mori K; Shimo M; Nakaike T; Yamashita K; Mashiba K; Kikuchi I; Marutsuka K; Ohshima K; Kato K; Akashi K
Blood Cell Ther; 2024 May; 7(2):37-40. PubMed ID: 38854403
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]